Risk from nonalcoholic fatty liver disease
Globally, nonalcoholic fatty liver disease is the most common form of chronic liver disease affecting children and adults and has been linked to an increase in obesity and type 2 diabetes.
Nonalcoholic fatty liver disease is known as a “silent” disease, since the disease begins with little or no symptoms with a build-up of fat in the liver, leading to fatty liver.
As the disease worsens, the inflamed liver leads to nonalcoholic fatty hepatitis. This is followed by fibrosis and cirrhosis of the liver, where the liver is scarred and the damage cannot be restored. A small number of patients with nonalcoholic fatty liver disease with cirrhosis will also develop liver cancer.
New drug to treat fatty liver disease – Photo 2.
Nonalcoholic fatty liver disease has been linked to an increase in obesity and type 2 diabetes.
Hopefully new treatments.
Kisspeptin in addition to playing important roles in the development of puberty and maintaining reproductive function, also has an effect on appetite and sexual attraction.
ASS. Moshmi Bhattacharya of Rutgers Robert Wood Johnson School of Medicine, and colleagues initiated this study to decode kisspeptin’s role in the liver, in healthy conditions and obesity.
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver, hopes for a new drug are superior
The researchers fed the mice a high-fat, high-sugar Western diet to cause obesity and nonalcoholic fatty liver disease. The mice were then given kisspeptin. The results showed that this hormone protected them from the development of fatty liver and fibrosis.
However, the researchers say further research is needed before introducing kisspeptin therapy into the treatment of patients